SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinicalstage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and prefunded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pr ...

MicroStockHub/iStock via Getty Images Investment Overview - Background To Recent Explosive Share Price Growth Foster City, California based Vaxcyte (NASDAQ:PCVX) completed its Initial Public Offering (IPO) in June 2020, raising $287.5m via the issuance of ~18m shares priced at $16 per share. At the time, the company discussed its business as follows: Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed t ...

Core Viewpoint - Vaxcyte, Inc. has initiated a public offering of $1.0 billion in common stock and pre-funded warrants to support its vaccine development efforts against bacterial diseases [1] Company Overview - Vaxcyte is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines to combat bacterial diseases [5] - The company is developing broad-spectrum conjugate and novel protein vaccines, including VAX-31, a Phase 3-ready 31-valent pneumococcal conjugate vaccine, and VAX-24, a 24-valent candidate currently in Phase 2 trials [5] - Vaxcyte's pipeline also includes candidates for Group A Strep infections, periodontal disease, and Shigella prevention [6] Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional $150 million in shares [1] - The offering is subject to market conditions, and there is no guarantee on its completion or terms [1] - A shelf registration statement for the securities was filed with the SEC and became effective on May 24, 2024 [3] Management and Underwriters - BofA Securities, Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities, and Mizuho are acting as joint book-running managers for the offering [2]

-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes -- -- At All Doses Studied, VAX-31 Was Observed to be Well Tolerated and Demonstrated a Safety Profile Similar to Prevnar 20® -- -- Topline Results Further Validate Potential of Vaxcyte's Carrier-Sparing Platform to Deliver BroadestSpectrum Pneumococcal Conjugate Vaccine Candidates th ...

Core Insights - Vaxcyte, Inc. is set to present topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine, aimed at preventing invasive pneumococcal disease in adults aged 50 and older [1] Company Overview - Vaxcyte is focused on engineering high-fidelity vaccines to combat bacterial diseases, developing broad-spectrum conjugate and novel protein vaccines [3] - The lead candidate, VAX-24, is a Phase 3-ready 24-valent PCV, while VAX-31 is the broadest-spectrum PCV candidate currently in clinical trials [3] - Both VAX-24 and VAX-31 aim to improve upon existing PCVs by covering serotypes linked to high case-fatality rates and antibiotic resistance [3] Technology and Innovation - The company utilizes modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, to produce complex vaccines more efficiently [4] - This innovative approach is designed to enhance the immunological benefits of the vaccines [4] Pipeline Candidates - Vaxcyte's pipeline includes several vaccine candidates: - VAX-A1 for preventing Group A Strep infections - VAX-PG for slowing or stopping periodontal disease progression - VAX-GI for preventing Shigella [4]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating Vaxcyte, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions [1] Group 1 - The investigation is on behalf of Vaxcyte's shareholders [1] - Shareholders interested in more information can contact the law firm for free [1] - The law firm specializes in representing shareholders affected by securities fraud and corporate misconduct [2]

Core Viewpoint - Vaxcyte, Inc. (PCVX) demonstrates strong momentum with significant price increases over the past quarter and year, outperforming the S&P 500 index [1][12]. Company Performance - Shares of Vaxcyte, Inc. have risen 27.43% over the past quarter and 79.98% over the last year, while the S&P 500 has increased by 7.48% and 21.12%, respectively [1]. - The stock currently holds a Momentum Style Score of B, indicating solid momentum potential [6][12]. - Over the past week, PCVX shares increased by 2.96%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.38% [14]. Earnings Outlook - In the last 60 days, one earnings estimate for PCVX has moved higher, while none have moved lower, resulting in a consensus estimate increase from -$3.96 to -$3.93 [15]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [15]. Trading Volume - The average 20-day trading volume for PCVX is 718,807 shares, which is a useful indicator of market interest and price movement [11].

"We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24 and VAX-31, toward late-stage clinical development, John will provide strategic insights across many aspects of our business." V ...

"I am delighted to join Vaxcyte's Board of Directors and be part of a team dedicated to using a cell-free technology platform to develop novel vaccines designed to address bacterial infections such as invasive pneumococcal disease," said Mr. Furey. "I look forward to contributing as we advance the Company's broadspectrum PCVs with the potential to expand coverage and improve upon the standard-of-care for both infants and adults." About Vaxcyte Forward-Looking Statements Janet Graesser, Senior Vice President ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 10-Q ___________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commissi ...